EUCTR2021-000665-32-PL进行中（未招募）1 期
Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Meets classification criteria for primary sjogren's syndrome (pSS) by the 2016 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) at the time of screening and was diagnosed with pSS no less than 26 weeks prior to screening
- •- At screening is seropositive for antibodies to pSS-associated antigen A Ro/sjogren's syndrome-related antigen [SSA])
- •- Total Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (clinESSDAI) score greater than or equal to (>=) 6
- •- At least one abnormal laboratory marker of pSS-related inflammatory disease activity, and at least low activity in one or more specified European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) domains
- •- It is recommended that participants are up to date on all
- •age-appropriate vaccinations prior to screening as per
- •routine local medical guidelines. For study participants
- •who received locally-approved (and including emergency
- •use-authorized) coronavirus disease 2019 (COVID-19)
- •vaccines recently prior to study entry, applicable local
- •vaccine labelling, guidelines, and standards-of-care for
- •participants receiving immune-targeted therapy will be
- •followed when determining an appropriate interval
- •between vaccination and study enrollment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 135
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •-Has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his/her pSS or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
- •- Comorbidities (for example, asthma, chronic obstructive pulmonary disease) which have required 3 or more courses of systemic glucocorticoids within the previous 12 months
- •- Has any unstable or progressive manifestation of pSS that is likely to warrant escalation in therapy beyond permitted background medications and/or has severely active pSS
- •- Has received oral cyclophosphamide within 3 months or intravenous (IV) cyclophosphamide within 6 months prior to first administration of study intervention
- •- Has sjogren's syndrome overlap syndromes where another confirmed autoimmune rheumatic or systemic inflammatory condition (for example, rheumatoid arthritis [RA], systemic lupus erythematosus [SLE], scleroderma, inflammatory bowel disease [IBD]) is the primary diagnosis or has clinical manifestations that, in the opinion of the investigator, or the sponsor or sponsor's representative are likely to interfere with the investigator's ability to assess pSS manifestations
研究者
相似试验
进行中（未招募）
1 期
A Study of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)Primary Sjogren's SyndromeMedDRA version: 21.0Level: LLTClassification code 10040766Term: Sjogren's diseaseSystem Organ Class: 100000004859EUCTR2021-000665-32-PTJanssen-Cilag International NV150
进行中（未招募）
1 期
A Study of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)EUCTR2021-000665-32-NLJanssen-Cilag International NV150
进行中（未招募）
1 期
A Study of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)EUCTR2021-000665-32-ESJanssen-Cilag International NV150
招募中
3 期
A Study of Vaccination with 9-valent Extraintestinal Pathogenic Escherichia coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Adults Aged 60 Years And Older with a History of Urinary Tract Infection in the Past 2 YearsInvasive extraintestinal pathogenic Escherichia coli disease (IED) preventionpreventionJPRN-jRCT2031210272akano Masayoshi18,556
尚未招募
3 期
A Global Study to find out the Effects of a Test Vaccine on prevention of harmful diseases caused by E.Coli spreading outside of the gut in Adults who are 60 Years And Older with a History of Urinary Tract Infection in the Past 2 Years.CTRI/2023/11/059617Janssen Vaccines & Prevention B.V.